Latest News - Parion Sciences

Monday, May 01, 2017 | Dry Eye, Partnerships, Parion Sciences, Shire

Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications

Shire and Parion Sciences announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investi…

Read the full story

Thursday, July 28, 2016 | Clinical Trials, Dry Eye, Parion Sciences

Parion Sciences Announces Initiation of Phase 2 Clinical Trial of P-321 for the Treatment of Dry Eye Disease

Parion Sciences announced it has initiated a phase 2 clinical trial of P-321 ophthalmic dolution in patients with dry eye disease. P-321 is an inhibitor of the epithelial sodium channels (ENaC) on the…

Read the full story